We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -7.02% | 1.325 | 1.30 | 1.35 | 1.425 | 1.325 | 1.425 | 2,958,047 | 14:52:56 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.25 | 10.24M |
From Apr 2019 to Apr 2024
TIDMSTX
RNS Number : 7531K
Shield Therapeutics PLC
11 July 2017
Shield Therapeutics plc
("Shield" or the "Company")
Grant of Share Options
London, UK, 11 July 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that the Company has today granted, in aggregate, 1,972,487 share awards in the form of options over Ordinary shares in the capital of the Company ("Ordinary Shares") under the Company's 2016 Long-term Incentive Plan ("LTIP") and the 2016 Company Share Option Plan ("CSOP"). The Company has granted 1,683,877 options under the LTIP and 288,610 options under the CSOP.
The LTIP options will be exercisable at a price of 1.5 pence per Ordinary Share, after a period of 3 years until the day before the tenth anniversary of the grant, subject to the achievement of clear performance criteria set out in the Company's Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com).
The CSOP options are exercisable at an exercise price of 157.5 pence per Ordinary Share from the third anniversary of grant until the day before the tenth anniversary of grant. There are no additional performance conditions attaching to the CSOP options.
This grant of options is part of the Company's long-term incentive arrangements designed to align the interests of the shareholders and executives.
In accordance with the requirements of the EU Market Abuse Regulation the following options have been granted to PDMRs under the LTIP and CSOP.
Hot Features
Premium
Total number
of LTIP Total number
LTIP options of CSOP options
options held following CSOP options held following
Name granted grant granted grant
Carl Sterritt,
CEO 263,512 572,736 19,048 19,048
Joanne Estell,
CFO 285,714 285,714 19,048 19,048
Paul Steckler,
PDMR 162,698 356,618 19,048 19,048
Mark Sampson,
PDMR 165,952 321,088 19,048 19,048
Following the grant of the LTIP and CSOP options, the total number of Ordinary Shares outstanding under share incentive schemes arrangements will be 3,014,749 representing 2.59% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
LTIP
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------------
a) Name Carl Sterritt Director / PDMR
Joanne Estell Director / PDMR
Paul Steckler PDMR
Mark Sampson PDMR
--- ------------------------- ----------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------
a) Position/status All PDMRs of Shield Therapeutics
--- ------------------------- ----------------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------------
a) Name Shield Therapeutics plc
--- ------------------------- ----------------------------------------
b) LEI 213800G74QWY15FC3W71
--- ------------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -------------------------------------------------------------------
a) Description Option over ordinary shares of 1.5p
of the each in the capital of the Company
financial ISIN of Ordinary Shares: GB00BYV81293
instrument,
type of
instrument
Identification
code
--- ------------------------- ----------------------------------------
b) Nature Grant of Options over ordinary shares
of the in accordance
transaction with the Company's Long Term Incentive
Plan
--- ------------------------- ----------------------------------------
c) Price(s) Exercise price: 1.5p
and volume(s) Volumes:
Carl Sterritt 263,512
Joanne Estell 285,714
Paul Steckler 162,698
Mark Sampson 165,952
--- ------------------------- ----------------------------------------
d) Aggregated
information 877,876
Exercise price: 1.5p
* Aggregated volume
* Price
--- ------------------------- ----------------------------------------
e) Date of 11 July 2017
the transaction
--- ------------------------- ----------------------------------------
f) Place Outside a trading venue
of the
transaction
--- ------------------------- ----------------------------------------
CSOP
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------------
a) Name Carl Sterritt Director / PDMR
Joanne Estell Director / PDMR
Paul Steckler PDMR
Mark Sampson PDMR
--- ------------------------- ----------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------
a) Position/status All PDMRs of Shield Therapeutics
--- ------------------------- ----------------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------------
a) Name Shield Therapeutics plc
--- ------------------------- ----------------------------------------
b) LEI 213800G74QWY15FC3W71
--- ------------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -------------------------------------------------------------------
a) Description Option over ordinary shares of 157.5p
of the each in the capital of the Company
financial ISIN of Ordinary Shares: GB00BYV81293
instrument,
type of
instrument
Identification
code
--- ------------------------- ----------------------------------------
b) Nature Grant of Options over ordinary shares
of the in accordance
transaction with the Company's Share Option Scheme
--- ------------------------- ----------------------------------------
c) Price(s) Exercise price: 157.5p
and volume(s) Volumes:
Carl Sterritt 19,048
Joanne Estell 19,048
Paul Steckler 19,048
Mark Sampson 19,048
--- ------------------------- ----------------------------------------
d) Aggregated
information
* Aggregated volume
76,192
Exercise price: 157.5p
* Price
--- ------------------------- ----------------------------------------
e) Date of 11 July 2017
the transaction
--- ------------------------- ----------------------------------------
f) Place Outside a trading venue
of the
transaction
--- ------------------------- ----------------------------------------
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500 Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer Nominated Advisor and Joint Broker Liberum Capital Limited Christopher Britton/Steve Pearce +44 (0)20 3100 2222 Joint Broker Peel Hunt LLP James Steel/Dr Christopher Golden +44 (0)20 7418 8900 Financial PR Advisor +44 (0)20 3709 5700 Consilium Strategic Communications shieldtherapeutics@consilium-comms.com Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUAVORBBABAAR
(END) Dow Jones Newswires
July 11, 2017 09:59 ET (13:59 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
